Research Progress of Inhibitors in mTOR Signal Transduction Pathway and Drug Resistance in Tumor

HE Chao^1,2, LIU Nan^1,2, ZHANG Rui^1,2*, TANG Jingfeng^1,2*

(¹Department of Biomedicine, School of Food and Biological Engineering, Hubei University of Technology, Wuhan 430068, China; ²National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan 430068, China)

Abstract:

mTOR (mammalian target of rapamycin) is an evolutionary protein kinase that senses multiple upstream stimuli to regulate cell growth, proliferation, metabolism and many other vital activities. The inactivation and abnormal activation of mTOR regulatory functions will lead to the occurrence of related tumors and diseases. In recent years, a variety of mTOR inhibitors have been used to treat tumors caused by abnormal regulation of this signaling transduction pathway. The latest advances in mTOR inhibitors for tumor treatment are listed, and the potential mechanisms by which tumor cells develop resistance to mTOR inhibitors are also explored. Therefore, in-depth study of the mTOR signal transduction pathway and its regulatory mechanism contributes to the development of new tumor treatment technologies.

CSTR: 32200.14.cjcb.2023.02.0011